This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity/Overweight
Status:
RECRUITING
Trial end date:
2026-08-06
Target enrollment:
Participant gender:
Summary
This study is to assess the safety and tolerability, PK characterisation, efficacy, and immunogenicity of the study intervention, and it allows assessment of the monotherapy or combination therapy of AZD6234 and AZD9550 in different sub-studies.